- Home
- SGMO vs TLSA Comparison
SGMO vs TLSA Comparison
Compare SGMO & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGMO | TLSA |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.2M | 164.1M |
| IPO Year | 2000 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SGMO | TLSA |
|---|---|---|
| Price | $0.18 | $1.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 27.1M | 200.0K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.20 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,567,000.00 | N/A |
| Revenue This Year | $107.15 | N/A |
| Revenue Next Year | $76.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 88.60 | N/A |
| 52 Week Low | $0.12 | $1.14 |
| 52 Week High | $0.77 | $2.60 |
Technical Indicators
Market Signals| Indicator | SGMO | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 37.98 | 55.53 |
| Support Level | N/A | $1.23 |
| Resistance Level | $0.55 | $1.54 |
| Average True Range (ATR) | 0.03 | 0.16 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 34.48 | 35.36 |
Price Performance
Historical ComparisonAbout SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.